创新药ETF国泰（517110）盘中涨超1.4%，连续5日迎资金净流入，关注创新为主的医药科技主线

Core Viewpoint - The innovation-driven pharmaceutical sector in China is experiencing significant growth, with a shift from traditional growth drivers to innovative ones, supported by demographic changes and advancements in technology [1]. Group 1: Industry Transformation - The Chinese pharmaceutical industry has completed a transformation from old to new growth drivers between 2015 and 2025, with innovation opening new growth trajectories for companies [1]. - Traditional pharmaceutical companies have successfully transitioned to innovation-focused models, enhancing their global competitiveness [1]. Group 2: Market Dynamics - The demand side is bolstered by an aging population and an increase in chronic disease prevalence, while the payment side benefits from stable growth in medical insurance revenues and the establishment of a multi-tiered payment system [1]. - The rapid development of new technologies, such as AI, brain-computer interfaces, and cancer early screening, is expected to drive further industry transformation and growth [1]. Group 3: Investment Opportunities - The Cathay Innovation Drug ETF (517110) has seen over 1.4% increase in intraday trading and has experienced net inflows for five consecutive days, indicating strong investor interest in innovation-focused pharmaceutical technology [1]. - The ETF tracks the SHS Innovation Drug Index (931409), which selects listed companies with strong R&D capabilities and growth potential in the biopharmaceutical and chemical pharmaceutical sectors [1].